{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:39:30Z","timestamp":1789850370086,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,10,25]],"date-time":"2013-10-25T00:00:00Z","timestamp":1382659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.ahj.2013.08.008","type":"journal-article","created":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T00:38:16Z","timestamp":1381883896000},"page":"218-225.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study"],"prefix":"10.1016","volume":"167","clinical-trial-number":[{"clinical-trial-number":"nct01105091","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Kelly M.","family":"Chin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Badesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan M.","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor F.","family":"Tapson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold I.","family":"Palevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Kawut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adaani","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade W.","family":"Benton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Lemarie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Bodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis J.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vallerie","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2013.08.008_bb0005","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2013.08.008_bb0010","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2013.08.008_bb0015","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2013.08.008_bb0020","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","article-title":"Updated evidence-based treatment algorithm in pulmonary arterial hypertension","volume":"54","author":"Barst","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2013.08.008_bb0025","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2013.08.008_bb0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/DDDT.S29916","article-title":"Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted","volume":"6","author":"Lambert","year":"2012","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.ahj.2013.08.008_bb0035","unstructured":"Veletri first and second generation prescribing information. http:\/\/www.veletri.com\/hcp-prescribing-information.asp. Accessed December 31, 2013."},{"key":"10.1016\/j.ahj.2013.08.008_bb0040","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1365-2125.2012.04301.x","article-title":"Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects","volume":"74","author":"Nicolas","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2013.08.008_bb0045","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2013.08.008_bb0050","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0735-1097(02)01744-8","article-title":"Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension","volume":"39","author":"Raymond","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2013.08.008_bb0055","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1183\/09031936.00130408","article-title":"Long-term outcome with intravenous iloprost in pulmonary arterial hypertension","volume":"34","author":"Hoeper","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ahj.2013.08.008_bb0060","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1378\/chest.07-0694","article-title":"Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels","volume":"132","author":"Chin","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2013.08.008_bb0065","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2013.08.008_bb0070","doi-asserted-by":"crossref","first-page":"807A","DOI":"10.1378\/chest.1387084","article-title":"Bloodstream infection rates in patients with pulmonary arterial hypertension treated with epoprostenol for injection (Veletri\u00ae): a PROSPECT registry analysis","volume":"142","author":"Frantz","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2013.08.008_bb0075","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.mayocp.2012.05.014","article-title":"Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY(R)","volume":"87","author":"Kitterman","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ahj.2013.08.008_bb0080","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1378\/chest.126.1.90","article-title":"Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension","volume":"126","author":"Oudiz","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2013.08.008_bb0085","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1086\/529552","article-title":"Bloodstream infections in patients given treatment with intravenous prostanoids","volume":"29","author":"Kallen","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ahj.2013.08.008_bb0090","first-page":"170","article-title":"Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension\u2014seven sites, United States, 2003-2006","volume":"56","author":"Centers for Disease Control and Prevention","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ahj.2013.08.008_bb0095","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1542\/peds.39.6.891","article-title":"Effect of sedation on oxygen consumption of children undergoing cardiac catheterization","volume":"39","author":"Baum","year":"1967","journal-title":"Pediatrics"},{"key":"10.1016\/j.ahj.2013.08.008_bb0100","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1203\/01.PDR.0000113768.50419.CD","article-title":"Oral glucose before venepuncture relieves neonates of pain, but stress is still evidenced by increase in oxygen consumption, energy expenditure, and heart rate","volume":"55","author":"Bauer","year":"2004","journal-title":"Pediatr Res"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870313005322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870313005322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:50:49Z","timestamp":1757569849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870313005322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0002870313005322"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2013.08.008","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2013.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}